Travere Therapeutics, Inc. (TVTX) News
Filter TVTX News Items
TVTX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
TVTX News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest TVTX News From Around the Web
Below are the latest news stories about TRAVERE THERAPEUTICS INC that investors may wish to consider to help them evaluate TVTX as an investment opportunity.
Travere Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceSAN DIEGO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that Eric Dube, Ph.D., president and chief executive officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, at 8:15 a.m. PT. A live webcast of the presentation will be accessible on the Investor page of Travere’s website at ir.travere.com/events-presentations, and a replay will be available for up to 30 days following the event. About Travere T |
High Growth Tech Stocks in the United States to WatchOver the last 7 days, the United States market has dropped 2.6%, yet it remains up by 23% over the past year with earnings forecasted to grow by 15% annually. In this dynamic environment, identifying high growth tech stocks involves looking for companies with strong innovation potential and robust financial health that can capitalize on these positive long-term trends. |
Investing in Travere Therapeutics (NASDAQ:TVTX) a year ago would have delivered you a 82% gainTravere Therapeutics, Inc. ( NASDAQ:TVTX ) shareholders have seen the share price descend 10% over the month. While... |
Travere Therapeutics to Present at Upcoming Investor ConferencesSAN DIEGO, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that company management will present in the following upcoming investor conferences in December: 7th Annual Evercore HealthCONx ConferenceTuesday, December 3, 2024, at 10:00 a.m. ET Citi 2024 Global Healthcare ConferenceWednesday, December 4, 2024, at 2:30 p.m. ET Live webcasts of the presentations will be accessible on the Investor page of Travere’s website at ir.travere.com/events-presentati |
Exploring Three High Growth Tech Stocks in the United StatesThe United States market has been flat in the last week yet it is up 32% over the past year with earnings forecast to grow by 15% annually. In this context, identifying high growth tech stocks that align with these robust market conditions can be crucial for investors looking to capitalize on potential opportunities. |
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)SAN DIEGO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that on November 10, 2024, the Compensation Committee of its Board of Directors granted inducement equity grants to six new employees, consisting of inducement restricted stock units, or RSUs, covering an aggregate of 24,400 shares of its common stock. These inducement RSUs are subject to the terms of Travere’s 2018 Equity Incentive Plan (“2018 Plan”) but were granted outside of the 2018 Plan |
Travere Therapeutics Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters’ Option to Purchase Additional SharesSAN DIEGO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced the completion of its previously announced underwritten public offering of 8,984,375 shares of its common stock at a price to the public of $16.00 per share, including 1,171,875 shares sold pursuant to the exercise in full of the underwriters’ option to purchase additional shares. All of the shares were sold by Travere. Including the option exercise, the aggregate gross proceeds from the offeri |
Travere Therapeutics Announces Pricing of Public Offering of Common StockSAN DIEGO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced the pricing of an underwritten public offering of 7,812,500 shares of its common stock at a price to the public of $16.00 per share. All of the shares are being sold by Travere. The gross proceeds from the offering are expected to be $125.0 million, before deducting the underwriting discounts and commissions and offering expenses. The offering is expected to close on November 12, 2024, subject |
Travere Therapeutics Announces Proposed Public Offering of Common StockSAN DIEGO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that it intends to offer and sell, in an underwritten public offering and subject to market and other conditions, shares of its common stock. All of the shares are being offered by Travere. In addition, Travere intends to grant the underwriters for the offering a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering. There can be no a |
Travere Therapeutics Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS LagsTravere Therapeutics ( NASDAQ:TVTX ) Third Quarter 2024 Results Key Financial Results Revenue: US$62.9m (up 70% from 3Q... |